Hutchison Chi-Med | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (42)

View All

Latest Posts

About This Stock More About This Stock
Week In Review: Suzhou Duality Out-Licenses Two ADCs To BioNTech In $1.7 Billion Deal
Article By: ChinaBio® Today
Saturday, April 8, 2023 2:20 PM EDT
Duality Biologics out-licensed global rights (ex-China) for two ADC candidates to BioNTech, Pfizer’s partner, for one of the two original COVID-19 vaccines in a deal worth $170 million upfront and up to $1.5 billion in milestone payments.
In this article: PFE, BNTX Also: MRK, VRNA, AMGN, HCM, TAK, SBHMY
Read
Week In Review: OrbiMed Plans To Raise $1.1 Billion For Fifth Asia Fund
Article By: ChinaBio® Today
Saturday, May 7, 2022 2:14 PM EDT
One year after raising $3.5 billion for three funds in 2021, OrbiMed, the world’s largest healthcare-dedicated investor, is back with plans for $4.75 billion in new funds despite the slowdown in biopharma exits over the past year.
In this article: AMGN, CHRS, HCM, BGNE, 1877.HK, 9939.HK, CNTB, 3692.HK, PALI
Read
Week In Review: Wuhan Binhui Raises $47 Million For Oncolytic Virus Products
Article By: ChinaBio® Today
Saturday, April 23, 2022 1:59 PM EDT
Wuhan Binhui Biotech closed a $47 million Series B financing to support its R&D of oncolytic virus products. Trevena, a Philadelphia-area CNS biopharma, closed a $40 million revenue-based financing from an affiliate of R-Bridge Healthcare Fund.
In this article: AZN, HCM, TRVN, IMAB, 1672.HK, 2126.HK, 300685.SZ
Read
Week In Review: Biopharma Deals Slow During Chinese New Year Week
Article By: ChinaBio® Today
Saturday, February 5, 2022 2:14 PM EDT
Amid a slow week, Shanghai's HanBio Therapeutics raised $40 million in a Series A financing to advance its innovative biologic products. HanBio is an early R&D company that was incubated by Sunshine Guojian Pharma.
In this article: HCM, 1877.HK, 9939.HK, 9926.HK, 688336.SS, BNIGF, XVIPF, 688192.SS
Read
Week In Review: Broncus Stages $200 Million Hong Kong IPO For Pulmonary Devices
Article By: ChinaBio® Today
Saturday, September 25, 2021 1:45 PM EDT
Broncus Holding, a Hangzhou pulmonary medical device company, completed a $200 million IPO on the Hong Kong exchange that valued the company at nearly $1.3 billion. The IPO was priced at the top end of the range, but Broncus' shares dropped 20%.
In this article: PFE, 1177.HK, HCM, 2616.HK, 1877.HK, 2162.HK, 9969.HK, 9926.HK, 2216.HK, 2171.HK
Read
All Posts

Latest Tweets for $HCM

No tweets yet!

PARTNER HEADLINES